Research Article

Do Monosodium Urate Crystals Reduce at Different Rates in Joints and Tendons During Urate-Lowering Therapy? A Dual-Energy Computed Tomography Study

📖 www.jrheum.org/cgi/content/...
@aucklanduni.bsky.social

#Gout #Tendon #Urate

Editorial

The Reversibility of Urate Tophi With Treat-to-Target in Gout: All Gone. Forever?

📖 doi.org/10.3899/jrhe...
@bcmhouston.bsky.social @uofalabama.bsky.social

#Gout #Tendon #Urate

📢 New Publication Alert!

🎓 Gout, Hyperuricemia and Crystal-Associated Disease Network (G–CAN) Conference 2025: Early-Career Investigators’ Abstracts!

📘 Full report and abstracts: www.mdpi.com/2813-4583/4/...

@g-cangout.bsky.social
#gout #hyperuricemia #urate #GCAN2025 #rheumatology

Treat-to-Target Urate-Lowering Treatment and Cardiovascular Outcomes in Patients With Gout This cohort study evaluates the association between achieving a serum urate treatment target lower than 6 mg/dL and cardiovascular events among patients with gout who were newly prescribed urate-lower...

En pacientes con gota a quienes se les prescribe tratamiento para reducir el urato, alcanzar un urato sérico menor de 6 mg/dL a los 12m se asocia con un riesgo menor de eventos CV adversos mayores a 5a #urate #CV jamanetwork.com/journals/jam...

📢 New Publication Alert!

📝 Title: Length of Monosodium #Urate Crystals in Synovial Fluid Based on Ultrasound Articular Deposits: Advancements in Crystallization Process!

👥 Authors: Elena Sansano-Muñoz et al.

🔗 Read the full article here: www.mdpi.com/2813-4583/3/...

Gout Remission Achievable With Pegloticase-Induced Urate-Lowering Therapy | Docwire News Intensive urate lowering with pegloticase achieved gout remission in 43% to 70% of patients after 52 weeks, depending on the definition used.

After 52 weeks, pegloticase achieved gout remission in 43% to 70% of patients, with rates varying by definition used. #gout #nephrology #urate #pegloticase docwirenews.com/post/gout-re...

Real-World Persistence of ULT in Gout Management | Docwire News Treat-to-target urate-lowering therapy (ULT) has shown efficacy in trials but a recent study finds long-term use of gout therapy to be inconsistent.

Treat-to-target ULT has shown efficacy in trials but a recent study finds long-term use of gout therapy to be inconsistent. #urate #nephrology #gout docwirenews.com/post/real-wo...

🏆 The Best #PhD Thesis #Award is back!

If you defended your PhD in 2025 on #gout, #urate, or crystal deposition disease, apply now!

🎁 CHF 1000 + certificate + free article voucher
📅 Deadline: 31 May 2026
📢 Winner: 31 July 2026

For more information: www.mdpi.com/journal/gucd...

Have you recently completed your #PhD in the field of #gout, #urate, and #crystaldepositiondisease? Don’t miss the opportunity to be recognized for your hard work and innovation! Only a few days left!

📌 Deadline: 31 May 2025
📝 How to apply: www.mdpi.com/journal/gucd...

Single-Center Study Examines ULT Guideline Adherence | Docwire News A study examined one medical center's adherence to gout management guidelines regarding the use of urate-lowering therapy (ULT) to lower uric acid (UA) levels.

Significant gaps exist in ULT guideline adherence across different demographics and comorbidities, a study found. #gout #urate #nephrology www.docwirenews.com/post/single-...

#PhDthesis #award

📣 📣📣The deadline is approaching!

🥼We are inviting young scholars in the field of #gout, #urate, and crystal deposition disease to send us their applications!

📍 The application process is open until the end of May!

🔗 For more information: www.mdpi.com/journal/gucd...

Target Serum Urate Achievement and CKD Progression in Patients With Gout and Kidney Disease This cohort study evaluates the use of urate-lowering therapy to achieve target serum urate levels in patients with gout and stage 3 chronic kidney disease.

En pacientes con gota y nefropatía crónica etapa 3, disminuir el urato sérico a <6 mg/dL no se asocia con mayor riesgo de nefropatía grave o terminal, por lo que debería optimizarse la terapia hipouricemiante para alcanzar la meta de urato sérico #urate #CKD #gout jamanetwork.com/journals/jam...

ULT for Gout Associated With Lower Risk of CKD Progression | Docwire News A post-hoc study of data from the CARES trial examined whether urate-lowering therapy (ULT) for gout might delay progression of chronic kidney disease (CKD).

It is believed that #hyperuricemia is a modifiable risk factor for CKD progression and that urate-lowering therapy could therefore delay CKD progression. #kidneydisease #urate